The seizure of more than 90,000 illegally imported tirzepatide ampoules — revealed by Brazilian TV network Globo — points to something far more serious than an isolated smuggling operation. It exposes a structural weakness in Brazil’s public health protection system.
This is not an ordinary product. Tirzepatide is a prescription drug used to treat obesity and requires strict cold-chain logistics, monitored transport, controlled storage, and full traceability. Any deviation from these standards can compromise both safety and efficacy.
Under Brazilian law, imported medicines must pass through the scrutiny of Agência Nacional de Vigilância Sanitária (Anvisa), specifically its ports, airports, and borders division. This is not excessive bureaucracy — it is the country’s primary sanitary barrier. When products bypass this control, they are contraband. When they pass through without proper enforcement, it suggests regulatory negligence.
Once these products enter the market outside official oversight — and are handled, repackaged, or sold without authorization — the legal classification is clear. Brazil’s Penal Code defines the importation and commercialization of medicines in violation of sanitary rules as a crime. This is not a regulatory debate; it is a public health offense.
The imbalance is striking. Pharmaceutical companies operating in Brazil are subject to constant inspections, supplier certification, international audits, and strict quality controls. Meanwhile, clinics and pharmacies using illegally imported inputs often face limited enforcement.
Strict compliance for those who follow the rules. Practical tolerance for those who circumvent them.
Isolated police operations are insufficient to address a systemic issue. As a federal agency, Anvisa cannot rely on fragmented local enforcement or shift responsibility to municipal authorities. Coordinating Brazil’s National Health Surveillance System is a federal mandate.
The public prosecutors’ office (Ministério Público) also plays a critical role in investigating accountability and protecting collective interests. Institutional inaction in the face of recurring violations must be examined with the same rigor applied to private misconduct.
Each illicit ampoule in circulation represents a real risk. Degraded biological drugs do not visibly lose potency, and adverse events do not come with proof of illegal origin.
What is needed is a coordinated national task force involving Anvisa, customs authorities, federal police, and prosecutors to block illegal imports, trace distributors, hold establishments accountable, and restore regulatory authority at Brazil’s borders.
Brazil has built, over decades, a regulatory reputation respected internationally. Allowing it to erode through omission represents a serious institutional setback.
When the state fails to prevent the circulation of irregular medicines, this is no longer an administrative issue. It becomes a systemic risk.
And in public health, systemic risks inevitably produce victims.
Nelson Mussolini is the executive president of Brazil’s pharmaceutical industry association (Sindusfarma).
(The opinions expressed in this article are the sole responsibility of the author and do not necessarily reflect the position of Brazil Stock Guide)
Leave a Reply